<DOC>
	<DOCNO>NCT02535312</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose methoxyamine give together cisplatin pemetrexed disodium see well work treat patient solid tumor mesothelioma spread place body usually cure controlled standard treatment ( advanced ) , mesothelioma respond pemetrexed disodium cisplatin carboplatin ( refractory ) . Methoxyamine may shrink tumor may also help cisplatin pemetrexed disodium work well make tumor cell sensitive drug . Drugs use chemotherapy , cisplatin pemetrexed disodium , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Giving methoxyamine together cisplatin pemetrexed disodium may better treatment solid tumor mesothelioma .</brief_summary>
	<brief_title>Methoxyamine , Cisplatin , Pemetrexed Disodium Treating Patients With Advanced Solid Tumors Mesothelioma That Can Be Removed Surgery Mesothelioma That Is Refractory Pemetrexed Disodium Cisplatin Carboplatin</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) recommend phase 2 dose ( RP2D ) combination TRC102 ( methoxyamine ) pemetrexed ( pemetrexed disodium ) cisplatin patient advance solid tumor . ( Arm A ) II . To describe toxicity TRC102 combine pemetrexed cisplatin dose study . ( Arm A ) III . To assess preliminary safety activity expansion cohort chemotherapy-naive advance unresectable malignant mesothelioma patient . ( Arm A ) IV . To describe response drug combination dose level . ( Arm A ) V. To detect activity combination TRC102 pemetrexed , evidence tumor response patient advance malignant mesothelioma previously treat pemetrexed cisplatin . ( Arm B ) SECONDARY OBJECTIVES : I . To describe pharmacokinetic parameter TRC102 give concurrent pemetrexed cisplatin . II . To evaluate pharmacodynamic parameter TRC102 give concurrently pemetrexed cisplatin . III . To explore feasibility establish pleural peritoneal effluent-derived cell line evaluate response culture pleural peritoneal mesothelioma cell cisplatin , pemetrexed , TRC102 . IV . To document objective clinical response TRC102 combination pemetrexed cisplatin . OUTLINE : This phase I , dose-escalation study methoxyamine follow phase II study . Patients assign 1 2 treatment arm . ARM A : Patients receive methoxyamine orally ( PO ) day 1-4 , pemetrexed disodium intravenously ( IV ) 10 minute , cisplatin IV 30-60 minute day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients may continue methoxyamine pemetrexed disodium beyond course 6 patient continue benefit treatment discretion treat physician . ARM B : Patients receive methoxyamine PO day 1-4 pemetrexed disodium IV 10 minute day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients may continue methoxyamine pemetrexed disodium beyond course 6 patient continue benefit treatment discretion treat physician . After completion study treatment , patient follow 8 week .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Thymoma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<criteria>Arm A dose escalation : patient histologically cytologically proven advanced solid tumor standard treatment available , current dose level cisplatin combination pemetrexed appropriate ; = &lt; 2 prior cytotoxic chemotherapy regimen Arm A dose level 4 ( 75 mg/m^2 cisplatin ) : patient histologically proven chemotherapynaive advance unresectable solid tumor pemetrexed combined cisplatin indicated regimen ( malignant mesothelioma , nonsmall cell lung cancer , ovarian cancer thymoma ) Arm A 14patients expansion cohort : patient histologically cytologically proven chemotherapy naive unresectable malignant pleural peritoneal mesothelioma Arm B ( first stage phase II TRC102 pemetrexed ) : patient malignant pleural peritoneal mesothelioma progress treat recur within 6 month treat pemetrexed cisplatin carboplatin frontline Prior pemetrexed allow except Arm A dose level 4 ( cisplatin 75 mg/m^2 ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ( Karnofsky &gt; = 70 % ) Life expectancy great 3 month Absolute neutrophil count &gt; = 1,500/uL Platelets &gt; = 100,000/uL Hemoglobin &gt; = 10.0 g/dl Prothrombin time international normalize ratio ( INR ) = &lt; 1.5 x upper limit normal ( ULN ) Total bilirubin &lt; 1.5 x ULN Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 2.5 x institutional ULN = &lt; 5 x ULN metastatic disease involve liver Serum creatinine = &lt; 1.5 x ULN calculate creatinine clearance &gt; = 60 ml/min/1.73 m^2 ( CockcroftGault method ) patient receive combination cisplatin pemetrexed &gt; = 45 ml/min/1.73 m^2 patient receive pemetrexed ; 24 hour urine creatinine clearance acceptable calculated creatinine clearance insufficient For patient enrolled arm A dose level 4 , arm A 14patients expansion cohort , arm B ( first stage phase II TRC102 pemetrexed ) measurable disease require accord Response Evaluation Criteria Solid Tumors ( RECIST ) criterion patient solid tumor modify RECIST criterion describe Byrne Novak patient malignant pleural mesothelioma ; pleural effusion ascites consider measurable disease Patients must able swallow whole capsule ; nasogastric gastrointestinal ( G ) tube administration allow Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , 4 month completion study drug ; woman become pregnant suspect pregnant partner participate study , inform treat physician immediately ; men treat enrolled protocol must also agree use adequate contraception prior study , duration study participation , 4 month completion TRC102 , pemetrexed cisplatin administration Nonchildbearing potential define ( medical reason ) : &gt; = 45 year age menses &gt; = 2 year , amenorrheic &lt; 2 year without hysterectomy oophorectomy folliclestimulating hormone value postmenopausal range upon pretrial ( screen ) evaluation , post hysterectomy , oophorectomy tubal ligation ; document hysterectomy oophorectomy must confirm medical record actual procedure confirm ultrasound ; tubal ligation must confirm medical record actual procedure otherwise patient must willing use 2 adequate barrier method throughout study , start screen visit though 4 month last dose study drug Ability understand willingness sign write informed consent document Patients chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover adverse event due agent administer 4 week earlier ; patient target therapy require wait 2 week due short halflife drug ; treatment bisphosphonates permit Patients receive investigational agent Patients active brain metastasis carcinomatous meningitis exclude clinical trial ; patient treat brain metastasis , whose brain metastatic disease remain stable great equal 4 week without require steroid antiseizure medication eligible participate History allergic reaction attribute compound similar chemical biologic composition TRC102 pemetrexed cisplatin No study perform assess potential metabolic transport interaction TRC102 ; part enrollment/informed consent procedure , patient counsel risk interaction agent , new medication need prescribe patient consider new overthecounter medicine herbal product ; case report form must capture concurrent use drug , overthecounter medication , alternative therapy Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study ; breastfeed discontinue mother treated TRC102 Human immunodeficiency virus ( HIV ) positive patient combination antiretroviral therapy ineligible Patients know disorder associated hemolysis Patients thromboembolic disease anticoagulation Patients prior cumulative cisplatin dose &gt; 300 mg/m^2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>